{
  "docId": "019de074-c46c-7261-862e-11078609bbd6",
  "docSlug": "94ed059236b735624310519badaf5152",
  "documentTitle": "Theravance Biopharma | Investor Conference Presentation Deck | 32 slides",
  "authorId": "theravance-biopharma",
  "authorName": "Theravance Biopharma",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 5,
  "pageCount": 32,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "cover",
  "function": "front_matter",
  "density": "balanced",
  "nDataPoints": 2,
  "notes": "Slide 5 of a corporate presentation.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-c46c-7261-862e-11078609bbd6/5",
  "deckHref": "/decks/019de074-c46c-7261-862e-11078609bbd6",
  "deckJsonHref": "/decks/019de074-c46c-7261-862e-11078609bbd6.json",
  "deckAnchorHref": "/decks/019de074-c46c-7261-862e-11078609bbd6#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.075,
        "w": 0.123,
        "x": 0.015,
        "y": 0.915
      },
      "kind": "image",
      "text": "Theravance Biopharma",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2284de30-3b3b-4c31-ace0-94c068e5f4ea",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.318,
        "w": 0.348,
        "x": 0.067,
        "y": 0.163
      },
      "kind": "image",
      "text": "YUPELRI revefenacin inhalation solution",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cd64acb0-d1ac-4c9b-8332-5ec3cecfda91",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.866,
        "x": 0.067,
        "y": 0.535
      },
      "kind": "list",
      "text": "FDA-approved for maintenance treatment of COPD\nFirst and only once-daily, LAMA (long-acting muscarinic agent) nebulized maintenance medicine for COPD\nCo-promotion agreement with VIATRISTM (35% / 65% Profit Share)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "89557087-19b0-4e71-b356-1b16c7cee189",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}